Breakout Watch: Nasdaq Profile (BSGM) Surges Green First Thing (Key Support Levels Strengthening?)

BSGM is making early green moves and needs the top spot on your watch-list quickly. Breakout Watch: Nasdaq Profile (BSGM) Surges Green First Thing (Key Support Levels Strengthening?) Ascendiant Capital Markets' Report - [$5.00 Price Target]( July 12th Dear Reader, BSGM is making early green moves and needs the top spot on your watch-list quickly. Right now, BSGM is trading above [2 very key lines]( of potential near term support. Those are its: - 5-Day Exponential Moving Average (EMA) - 13-Day EMA If support starts building at those levels, it could propel BSGM towards its 50-Day Simple Moving Average (SMA) at around $1.29. That's where things could get wild. As a potential resistance line, if that 50-Day SMA was to be broken down, it could attract a ton of attention to this Nasdaq profile. Why? Simple. It would be trading above 3 of the most important lines of potential support in its 13-Day EMA, its 50-Day SMA, and its 200-Day SMA. Drop everything right now and get BSGM on radar quickly. ----- Let's get straight to the thick of it. Coming off Monday's alert that turned in a strong 2-day run of approximately 13%, we're turning our attention to a Medtech profile currently trading on the Nasdaq CM. This company's innovative approach and unwavering commitment to developing revolutionary technology may soon garner significant exposure. Should that happen, it could have a lasting impact on the healthcare sector. The company's state-of-the-art technology is already creating ripples in the industry, and it has helped to forge several partnerships and agreements with top-notch institutions and experts in the field. Having an unwavering focus on pushing boundaries, the company continues to discover novel ways to enhance patient care and outcomes. With the exciting possibilities that artificial intelligence (AI) brings to healthcare, this company recently announced the advancement of R&D on a game-changing platform that could disrupt the medical community to its core. Plus, with new data from recent studies suggesting improvements on conventional procedural methods, based on the company's flagship device, this profile may soon become a huge attention-getter as a commercial launch nears. And when it comes to this profile's chart history, "explosive" may be the best word to describe it. Massive green spikes litter this profile's 1-year chart as it has exploded for big triple-digit and double-digit surges short term. Drop everything and pull up this Nasdaq breakout idea: *BioSig Technologies, Inc. (BSGM)* BioSig Technologies is an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare’s biggest priorities—saving time, saving costs, and saving lives. And right now, BSGM has several potential catalysts to familiarize yourself with. Check them out: No. 1 - A 2023 Analyst Provided Target Suggests Upwards Of 300% Potential Upside No. 2 - Company Inks New Collaboration Deal To Advance AI In Electrophysiology No. 3 - New Data Puts Company On Track For A Successful Commercial Launch No. 4 - An Explosive Chart History Oozing With Major Breakout Splashes But more on those in a second... Reimagining What’s Possible In Cardiac Care BioSig Technologies is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. By leveraging a first-of-its-kind combination of hardware and software, the company's technology delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines. The Consequences Of Mixed Signals In Electrophysiology Signal Blindness Noise from the lab environment substantially interferes with the conventional systems ability to process and visualize low amplitude signals – resulting in blind spots and loss of relevant data. Identifying Complex Signals While catheter advancements have yielded many advantages in EP cases, the burden of capturing clarity of the signal (i.e. ’chasing the signal’) remains on the shoulders of EPs as they rely on antiquated signal technology. Inefficiency Poor signal quality leads to more time spent in expensive environments and the burden of the ongoing search for the next best thing. Rising Cost of Care The cost of delivering high quality care to patients requires doing more with less — increasing pressure on physicians to find ways to improve procedural workflow. The PURE EP™ Platform With the PURE EP™ Platform, BioSig is removing unnecessary distractions to preserve the value of cardiac signals delivering clear actionable insights for today’s EPs. Capturing The Entire Range Of Intracardiac Signals PURE EP™ displays potentially critical clinical data, so electrophysiologists can see more, clearly. Advanced Signal Acquisition Hardware Less Noise Low-noise proprietary architecture enables acquisition of high-fidelity signals in the original, unfiltered format. The PURE EP™ Main System Unit (MSU) topology incorporates advanced shielding and very low noise front-end components. Higher Definition PURE EP™ supports a large frequency bandwidth and linear signal acquisition to accurately display complex fractionated signals, even at lower amplitudes and higher frequencies. Wider Range An expanded dynamic range retains cardiac signal details and reduces saturation. PURE EP™ combines a low-noise signal architecture with a fixed range up to 500mV, so signals are rarely clipped or limited by quantization noise. Unipolar Signals PURE EP™ incorporates an innovative WCT+™ design for acquiring unipolar signals, relying on a common front-end circuitry similar to how bipolar intracardiac signals are acquired. Intelligent Digital Signal Processing & Analysis Software New PURE EP™ Software Version 6 with ACCUVIZ™ Software Module lets you do even more with best-in-class intracardiac signal acquisition to improve clinical workflow while focusing on what matters most. Grab Key Details And Sources Here: [Company Website]( - [Company Presentation]( ----- As mentioned above, BSGM has several potential breakout catalysts to soak in right now. Here they are: No. 1 BSGM Potential Catalyst - A 2023 Analyst Provided Target Suggests Upwards Of 300% Potential Upside In February of 2023, [Ascendiant Capital Markets']( analyst, Edward Woo, tagged BSGM with a $5.00 target. From its closing valuation on Tuesday, that provides BSGM with an upside potential over 300%. Here's some key highlights from the report: Focused on PURE EP: The company has developed the PURE EP system whose enhanced signal acquisition, digital signal processing, and analysis provides key data used during ablation of cardiac arrhythmias. The PURE EP System is a FDA 510(k) cleared (in August 2018) non-invasive class II device. Targeting heart disease: In the U.S., heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups, contributing to about 20 - 25% of deaths in the U.S. every year. Every 40 seconds, someone in the U.S. has a heart attack. Arrhythmia is a leading condition and contributing cause for heart disease. PURE EP system: The PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP (Electrophysiology) System is designed to provide essential diagnostic signals during all types of cardiac catheter ablations (a procedure that involves delivery of energy through the tip of a catheter to correct heart rhythm arrhythmias). PURE EP is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP benefits: PURE EP’s features may allow physicians to better determine precise ablation targets, strategy, and end point of procedures with the objective of reducing the need for patients to undergo multiple procedures, and to allow for less experienced EP physicians to perform more complex procedures. It is estimated that over half of cardiac ablation procedures are not successful (requires additional ablation procedures). 3,000 procedures and growing: To date, more than 3,000 patient procedures have been conducted with the PURE EP System by more than 80 electrophysiologists across 21 different clinical sites in the U.S. The PURE EP System is currently in national commercial launch in the U.S. at healthcare systems such as Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute. Market opp's: According to Health Research International, it is estimated that there are 8,163 global EP lab rooms (with an estimated 3,500 in the U.S.) performing catheter ablations. The rapidly growing EP market is projected to reach $16Bn by 2028 (+11.2% annual growth rate). However, challenges exist: BioSig operates in a highly competitive environment and competes against a wide range of other technologies. There is the chance that competing technologies may challenge BioSig technologies or that existing standard of care methods remains the industry standard. ... Current valuation attractive: We calculate a 12-month price target for shares of BioSig to be $5.00 based on a NPV analysis, representing significant upside from the current share price. We believe this valuation appropriately balances out the company’s high risks with its high growth prospects and large upside opp's. ----- No. 2 BSGM Potential Catalyst - Company Inks New Collaboration Deal To Advance AI In Electrophysiology BioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare Westport, CT, June 27, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it is advancing the research and development of an artificial intelligence (AI) medical device platform in collaboration with technical advisory partner Reified Labs. The platform’s foundational machine learning model is anticipated to be based on integrated healthcare datasets, beginning with ECG and IECG data acquired by BioSig’s first product, the PURE EP™ Platform. Electrophysiology-focused technological solutions developed under the terms of the collaboration may be integrated into PURE EP™ technology for potential commercial application. Cambridge, Massachusetts-based Reified Labs, a provider of advanced artificial intelligence-focused technical advisory services to the life sciences industry, is led by Harvard- and MIT-trained Dr. Alexander D. Wissner-Gross, an award-wi-nning computer scientist, physicist, entrepreneur, and author. BioSig's prior collaboration with Reified, established in 2019, has yielded multiple patent applications1 and a research publication2 on initial discoveries in AI-enhanced electrocardiogram lead placement mapping. ... “The application of AGI and digital signal processing to analyzing signals from the so-called human ‘electrome’ – the set of all electrical and ionic currents in the human body – continues to present a promising opp. for realizing key medical advances relating to disorders of the peripheral nervous system,” said Dr. Wissner-Gross. “We look forward to our forthcoming collaboration with BioSig.” [Read the full article here.]( ----- No. 3 BSGM Potential Catalyst - New Data Puts Company On Track For A Successful Commercial Launch New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6Bn Annual Atrial Fibrillation Market WESTPORT, CT / ACCESSWIRE / May 25, 2023 / Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies' (NASDAQ:BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in New Orleans, LA, last week. The platform's precision signal-capturing technology is meant to improve the speed, accuracy and precision of cardiac ablation, a widely-used surgery to treat atrial fibrillation. All three studies showed significant improvements over the conventional methods used for the procedure, putting BioSig on track for a successful commercial launch of the platform in a global cardiac ablation market projected to exceed $14Bn by 2032. ... PURE EP Platform Captures Real-Time Feedback Other Tech Misses While the Ablation Index uses surrogate measures, including contract force, power and time, PURE EP uses raw unipolar signals to generate real-time feedback. In the past, studies have suggested that using these unipolar signals could improve the accuracy of ablations, but actually capturing those signals proved impractical as there was too much noise interference from the operating room as well as the radio frequency equipment used in the procedure. The PURE EP platform's proprietary hardware and software can dampen noise interference and pick up the unipolar signal clearly and in real-time with a level of precision that other platforms reportedly can't achieve. To understand how much of a difference this improved signal-capturing tech made in the operating room, the three studies presented at Heart Rhythm 2023 each compared a new cardiac ablation procedure using BioSig's PURE EP Platform to the current best-in-class Ablation Index-guided procedure. In the first study, the new procedure was able to achieve identical results in both swine and human models in a fraction of the time. Where the standard ablation index-guided procedure had an ablation time of 24 seconds, the PURE EP-guided procedure's ablation time was just eight seconds. In the second study, doctors performed the surgery without the 3D mapping system traditionally used. Instead, they were able to accurately place and space lesions in swine models guided only by the PURE EP Platform's unipolar morphology. In the third study, researchers found that the platform could successfully differentiate between healthy tissue and scar tissue, allowing doctors to better measure lesions for more precise lesion placement. Already used in several hospitals across the country, BioSig is optimistic that the non-invasive platform could see even wider spread adoption of the technology following the release of these three studies demonstrating the improved speed, accuracy and precision of cardiac ablations done with the PURE EP Platform. [Read the full article here.]( ----- No. 4 BSGM Potential Catalyst - An Explosive Chart History Oozing With Major Breakout Splashes Take a quick look at BSGM's 1-year chart below: You see the significant surges this chart is displaying? Here's a quick history lesson: #1. 7/28/22: From a low that session of $.50, BSGM erupted to a high of $1.25 on 8/25/22 for a move of 150%. #2. 11/9/22: From a low that session of $.2514, BSGM cruised to a high of $1.46 on 2/13/23 for a surge of 480%. #3. 3/20/23: From a low that session of $.85, BSGM climbed to a high of $1.65 on 5/25/23 for a run of 94%. Huge runs in the short term. BSGM needs to be watched with a careful eye. ----- BSGM Recap - The Top Potential Catalysts To Know Right Now No. 1 - A 2023 Analyst Provided Target Suggests Upwards Of 300% Potential Upside No. 2 - Company Inks New Collaboration Deal To Advance AI In Electrophysiology No. 3 - New Data Puts Company On Track For A Successful Commercial Launch No. 4 - An Explosive Chart History Oozing With Major Breakout Splashes ----- Coverage is officially initiated on BSGM. When time allows, do this: Get BSGM on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) Fierce | 401 W. Atlantic Ave, Ste R10 Unit #271, Delray Beach, FL 33444 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net